Skip to main navigation Skip to search Skip to main content

Antenatal magnesium sulfate to prevent cerebral palsy

  • Amy K. Keir
  • , Emily Shepherd
  • , Sarah McIntyre
  • , Alice Rumbold
  • , Charlotte Groves
  • , Caroline Crowther
  • , Emily Joy Callander

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Magnesium sulfate given to women before birth at <30 weeks' gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks' gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.

Original languageEnglish
Pages (from-to)F225-F227
Number of pages3
JournalArchives of Disease in Childhood: Fetal and Neonatal Edition
Volume107
Issue number2
DOIs
Publication statusPublished - Mar 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
©

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • health services research
  • neonatology

Fingerprint

Dive into the research topics of 'Antenatal magnesium sulfate to prevent cerebral palsy'. Together they form a unique fingerprint.

Cite this